Real-World Effectiveness and Safety of Virulina in Adults with Respiratory and Post-Viral Inflammatory Conditions: A Multicenter Retrospective Cohort Study
Abstract
Background: Respiratory illnesses are a major contributor to global morbidity. Conventional treatments, though effective, are constrained by adverse effects and incomplete recovery. Virulina, a standardized polyherbal formulation with antiviral and immunomodulatory activity, was evaluated for its real-world effectiveness and safety. Methods: This multicenter, retrospective, post-marketing cohort study analyzed the treatment records of 300 adults (aged 18–65 years) treated with Virulina across five Ayurvedic outpatient clinics in India. Patients received 1 g TID for 14–28 days. The primary outcome was safety, assessed by adverse event incidence. Secondary outcomes included symptom resolution, inflammatory and hematological biomarker changes, and physician-rated vitality scores. Results: Of 300 patients (56% male, mean age 45 years), 70% presented with symptoms, and 54.4% had comorbidities. Virulina therapy yielded marked symptom resolution, with reductions ranging from 75.9% in bronchitis, 78.3% in bronchial asthma, 82.6% in post-viral musculoskeletal symptoms, 84.1% in lung inflammation, to 89.7% in viral respiratory infections (all p < 0.001. Laboratory outcomes showed significant normalization: CRP declined by up to 96.8%, D-dimer by 55%, and leukocyte and eosinophil counts by 48–65% (p < 0.001 for all). Physician-assessed vitality and immune modulation scores improved by 89 - 96%, correlating with clinical recovery. Notably, no adverse events or therapy discontinuations were reported, underscoring an excellent safety profile. Conclusion: Virulina demonstrated substantial symptom improvement, biomarker normalization, and excellent tolerability across a heterogeneous outpatient population with respiratory illnesses. These findings highlight its potential as a safe, accessible adjunct to standard care, meriting validation in prospective randomized controlled trials.
Keywords: lower and upper respiratory tract infections, post-viral inflammation, Virulina
Keywords:
lower and upper respiratory tract infections, post-viral inflammation, VirulinaDOI
https://doi.org/10.22270/jddt.v15i10.7399References
1. Niederman MS, Torres A. Respiratory infections. European Respiratory Review. 2022;31:220150. https://doi.org/10.1183/16000617.0150-2022 PMid:36261160 PMCid:PMC9724828
2. Labaki WW, Han MK. Chronic respiratory diseases: a global view. The Lancet Respiratory Medicine. 2020;8(6):585-596. https://doi.org/10.1016/S2213-2600(20)30157-0 PMid:32526184
3. Long Y, Zheng Y, Li C, et al. Respiratory pathogenic microbial infections: a narrative review. International Journal of Medical Sciences. 2024;21(5):654-670. https://doi.org/10.7150/ijms.93628 PMid:38617014 PMCid:PMC11008481
4. Azoulay É, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Medicine. 2020;46(2):298-314. https://doi.org/10.1007/s00134-019-05906-5 PMid:32034433 PMCid:PMC7080052
5. Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. Redox Biology of Respiratory Viral Infections. Viruses. 2018;10(8):392. https://doi.org/10.3390/v10080392 PMid:30049972 PMCid:PMC6115776
6. Holland AE, Lewis A. Evidence-based management of symptoms in serious respiratory illness: what is in our toolbox? European Respiratory Review. 2024;31:0205-2024. https://doi.org/10.1183/16000617.0205-2024 PMid:39477357 PMCid:PMC11522974
7. MacRae C, Whittaker H, Mukherjee M, et al. Deriving a Standardised Recommended Respiratory Disease Codelist Repository for Future Research. Pragmatic and Observational Research. 2022;13:1-10. https://doi.org/10.2147/POR.S353400 PMid:35210898 PMCid:PMC8859726
8. Sadekar N, Boislève F, Dekant W, et al. Identifying a reference list of respiratory sensitizers for the evaluation of novel approaches to study respiratory sensitization. Critical Reviews in Toxicology. 2021;51(10):1-18. https://doi.org/10.1080/10408444.2021.2024142 PMid:35142253
9. Chi-Leung D. The big 5 respiratory diseases give insight into respiratory health and beyond. Respirology. 2023;28(3):234-236. https://doi.org/10.1111/resp.14499 PMid:36988232
10. Couch RB, Englund JA. Respiratory Viral Infections in Immunocompetent and Immunocompromised Persons. The American Journal of Medicine. 1997;102(3A):2-9. https://doi.org/10.1016/S0002-9343(97)00003-X PMid:10868136
11. Herrera Garcia JC. Update on respiratory diseases. The Veterinary Clinics of North America. Small Animal Practice. 2020;50(6):1121-1135. https://doi.org/10.1016/j.cvsm.2020.06.008 PMid:32682546
12. Phelan P, Landau L, Olinsky A, Williams H. Respiratory Illness in Children. Archives of Disease in Childhood. 1975;50(12):918-925. https://doi.org/10.1136/adc.50.12.967-b
13. Laguna-Muñoz D, Jiménez-Peinado A, Jaén-Moreno MJ, et al. Respiratory disease in people with bipolar disorder: a systematic review and meta-analysis. Molecular Psychiatry. 2024;29(11):1-12. https://doi.org/10.1192/j.eurpsy.2025.13 PMid:39904730 PMCid:PMC11883783
14. MacRae C, Whittaker H, Mukherjee M, et al. POR_A_353400 1..8. [Unpublished/Preprint].
15. Azer S. Is Wikipedia a reliable learning resource for medical students? Evaluating respiratory topics. Advances in Physiology Education. 2015;39(1):5-14. https://doi.org/10.1152/advan.00110.2014 PMid:25727464
16. Bont L, Checchia PA, Fauroux B, et al. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infectious Diseases and Therapy. 2016;5(3):271-298. https://doi.org/10.1007/s40121-016-0123-0 PMid:27480325 PMCid:PMC5019979
17. Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: Current and emerging treatment options. Clinicoecon Outcomes Res. 2014;6:217-225. https://doi.org/10.2147/CEOR.S60710 PMid:24812523 PMCid:PMC4008286
18. Lim JY, Oh E, Kim Y, et al. Enhanced oxidative damage to DNA, lipids, and proteins and levels of some antioxidant enzymes, cytokines, and heat shock proteins in patients infected with influenza H1N1 virus. Acta Virologica. 2014;58(3):253-260. https://doi.org/10.4149/av_2014_03_253 PMid:25283860
19. Wang M, Luo X, Xu S, et al. Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013. The Lancet Respiratory Medicine. 2019;7(1):35-45. https://doi.org/10.1016/S2213-2600(18)30432-6 PMid:30482646
20. Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1923-1994. https://doi.org/10.1016/S0140-6736(18)32225-6 PMid:30496105
21. Reyfman PA, Washko GR, Dransfield MT, et al. Defining impaired respiratory health: a paradigm shift for pulmonary medicine. American Journal of Respiratory and Critical Care Medicine. 2018;198(4):440-446. https://doi.org/10.1164/rccm.201801-0120PP PMid:29624449 PMCid:PMC6118019
22. Soriano JB, Kendrick P, Paulson K, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Respiratory Medicine. 2020;8(6):585-596. https://doi.org/10.1016/S2213-2600(20)30105-3 PMid:32526187
Published
Abstract Display: 128 
PDF Downloads: 117 PDF Downloads: 22 How to Cite
Issue
Section
Copyright (c) 2025 Baburao Vikram, Sandeep Arora , Dishya Sewda, Anil Sharma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.